Treatment benefit of upfront autologous stem cell transplantation for newly diagnosed multiple myeloma: a systematic review and meta-analysis

BACKGROUND: Upfront high-dose therapy (HDT) followed by autologous stem cell transplantation (ASCT) remains a profitable strategy for newly diagnosed multiple myeloma (MM) patients in the context of novel agents. However, current knowledge demonstrates a discrepancy between progression-free survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Chi-Maw, Chang, Lih-Chyun, Shau, Wen-Yi, Chen, Chi-Ling, Yao, Chi-Yuan, Tien, Feng-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10190007/
https://www.ncbi.nlm.nih.gov/pubmed/37193978
http://dx.doi.org/10.1186/s12885-023-10907-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10190007/
https://www.ncbi.nlm.nih.gov/pubmed/37193978
http://dx.doi.org/10.1186/s12885-023-10907-1

Ejemplares similares